Watch Dr. Ramalingam discuss the latest #NSCLC updates from #WCLC24 - https://bit.ly/24Stage3LungY
A New Standard of Care: Dr. Ramalingam Discusses LAURA Results, Implications With the Two Onc Docs
Dr Ramalingam on Updates in Lung Cancer Following the 2024 ASCO Annual Meeting
The Two Onc Docs Reflect on Interviewing Dr. Ramalingam About Historic LAURA Plenary
Dr. Ramalingam on Winship's cancer research and clinical care
Dr. Ramalingam Discusses the Results of the Phase III REVEL Study in NSCLC
DR RAMALINGAM LAP VVF REPAIR 8TH LAP URO WORKSHOP
Dr. Ramalingam on Emerging Combination Regimens in NSCLC
What is Dr. Ramalingam’s vision for the journal Cancer?
Dr. Ramalingam on Treatment Parameters for Osimertinib in Lung Cancer
Dr. Ramalingam on the Use of Osimertinib in Clinical Trial and Real-World Settings
What are Dr. Ramalingam’s overarching goals for the journal Cancer?
Ramalingam’s Ultimate Solution | Live Event with Dr. Pillai | Oct. 5, 2022
Dr. Ramalingam on Pembrolizumab and Chemotherapy in NSCLC
Dr. Ramalingam on the Safety of Tecemotide
Dr. Ramalingam on New Data for EGFR Inhibitors for Lung Cancer
Dr. Ramalingam on Avelumab Plus Lorlatinib in NSCLC
feedbck Dr Ramalingam AnnaUniv
Dr. Ramalingam on the Significance of the FLAURA Trial in NSCLC
Dr Ramalingam on Pfizer Study
